78 related articles for article (PubMed ID: 2709892)
1. [Behavior of serum CA 72.4 in patients with non-tumor pathologies. Preliminary results].
Sagredo E; Soriano A; Pombo L; Ruibal A
Med Clin (Barc); 1989 Jan; 92(2):78-9. PubMed ID: 2709892
[No Abstract] [Full Text] [Related]
2. [Serum CA 15.3 in women with non-tumor breast pathologies. Initial results].
Ruibal A; Colomer R; Gris JM; Genollá J
Med Clin (Barc); 1986 Sep; 87(9):393-4. PubMed ID: 3467152
[No Abstract] [Full Text] [Related]
3. Seric CA 19.9 levels in patients with non tumoral pathologies. Our experience in 892 cases.
Encabo G; Ruibal A
Bull Cancer; 1986; 73(3):256-9. PubMed ID: 3463370
[No Abstract] [Full Text] [Related]
4. [Detection of "pathologic" fraction of serum lipoproteins in patients with biliary tract, liver and non-hepatic diseases].
Diachina EG
Lab Delo; 1973; 8():485-6. PubMed ID: 4130981
[No Abstract] [Full Text] [Related]
5. [The behavior of blood CA 15.3 in patients with non-tumor pathologies. Preliminary results].
Ruibal A; Guarga A; Encabo G; Gris JM
Med Clin (Barc); 1986 Feb; 86(6):262. PubMed ID: 3458017
[No Abstract] [Full Text] [Related]
6. [Behavior of serum CA 125 in hepatopathy patients].
Ruibal A; Encabo G; Capdevila JA; Aguadé S; Gefaell R; Ribera E; Martínez-Vázquez JM
Med Clin (Barc); 1984 Mar; 82(12):560. PubMed ID: 6738156
[No Abstract] [Full Text] [Related]
7. MCA and CA 15.3 serum levels in non-malignant diseases. Some preliminary results.
Soriano A; Allende MT; Vizoso F; Fernández García J; Vivanco J; Ruibal A
Int J Biol Markers; 1990; 5(1):46-7. PubMed ID: 2230351
[No Abstract] [Full Text] [Related]
8. [Insulinemia in patients with extrapancreatic diseases of various types].
Cozzolino G; Marri G; Giannini R
Boll Soc Ital Biol Sper; 1969 Nov; 45(21):1350-3. PubMed ID: 5311798
[No Abstract] [Full Text] [Related]
9. [Studies on lactacidemia and its clinical significance. III. Results in patients with various diseases].
Gil Extremera B; Rico Irles J; Núñez Carril J; Raya Muñoz J
Rev Clin Esp; 1974 Oct; 135(1):35-46. PubMed ID: 4457979
[No Abstract] [Full Text] [Related]
10. Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay.
Guadagni F; Roselli M; Cosimelli M; Spila A; Cavaliere F; Tedesco M; Arcuri R; Abbolito MR; Casale V; Pericoli MN; Vecchione A; Casciani CU; Greiner JW; Schlom J
Cancer Res; 1996 Nov; 56(22):5293-8. PubMed ID: 8912871
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
[TBL] [Abstract][Full Text] [Related]
12. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
[TBL] [Abstract][Full Text] [Related]
13. Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer).
Ruibal A; Encabo G; Genollá J; Guarga A; Urrutia A; Colomer R
Bull Cancer; 1986; 73(1):94-5. PubMed ID: 3465383
[No Abstract] [Full Text] [Related]
14. [Clinical evaluation of serum CA-50 measurement in breast diseases --relation to the progress of breast cancer].
Shiga T; Kawauchi A; Kamiya K; Ishii J; Uzawa R; Gomi K
Rinsho Byori; 1986 Nov; 34(11):1339-45. PubMed ID: 3469447
[No Abstract] [Full Text] [Related]
15. [Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER].
Buda F; Aragona P; Giani G; Sisto R; Di Nardo G; Binotto F; Gangemi P; De Zerbi T; Gentile G; Papadia A
G Ital Oncol; 1989; 9(2-3):67-72. PubMed ID: 2767730
[TBL] [Abstract][Full Text] [Related]
16. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
17. [Carbohydrate antigen (CA-19-9) in the blood serum of patients with benign and malignant liver diseases].
Ametov AS; Kasatkin IuN; Mit'kov VV; Gur'eva IV
Med Radiol (Mosk); 1985 Mar; 30(3):39-41. PubMed ID: 3856723
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
Collazos J; Genolla J; Ruibal A
Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
[TBL] [Abstract][Full Text] [Related]
19. [Sialic acid of glycoproteins and seromucoid in liver diseases].
Kaniak J; Mejbaum-Katzenellenbogen ; Jelewska-Kaniakowa Z; Kudrewicz-Hubicka Z; Kowal-Gierczak B
Pol Tyg Lek; 1969 Dec; 24(51):1953-5. PubMed ID: 5365679
[No Abstract] [Full Text] [Related]
20. [Content of glycoproteids in the blood serum of the patients with chronic inflammatory diseases of the biliary tract and liver].
Borevskaia BD; Gubergrits EA
Vrach Delo; 1967 Feb; 2():14-6. PubMed ID: 5617012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
